Review



dynamic pbpk modeling software gastroplustm version 9.9  (Simulations Plus Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Simulations Plus Inc dynamic pbpk modeling software gastroplustm version 9.9
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Dynamic Pbpk Modeling Software Gastroplustm Version 9.9, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dynamic pbpk modeling software gastroplustm version 9.9/product/Simulations Plus Inc
    Average 90 stars, based on 1 article reviews
    dynamic pbpk modeling software gastroplustm version 9.9 - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis"

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2025.1555276

    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Figure Legend Snippet: Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

    Techniques Used: Concentration Assay, Clinical Proteomics

    The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.
    Figure Legend Snippet: The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

    Techniques Used: Clinical Proteomics



    Similar Products

    dynamic pbpk modeling software gastroplustm version 9.9  (Simulations Plus Inc)
    90
    Simulations Plus Inc dynamic pbpk modeling software gastroplustm version 9.9
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Dynamic Pbpk Modeling Software Gastroplustm Version 9.9, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dynamic pbpk modeling software gastroplustm version 9.9/product/Simulations Plus Inc
    Average 90 stars, based on 1 article reviews
    dynamic pbpk modeling software gastroplustm version 9.9 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

    Journal: Frontiers in Pharmacology

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

    doi: 10.3389/fphar.2025.1555276

    Figure Lengend Snippet: Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

    Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

    Techniques: Concentration Assay, Clinical Proteomics

    The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

    Journal: Frontiers in Pharmacology

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

    doi: 10.3389/fphar.2025.1555276

    Figure Lengend Snippet: The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

    Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

    Techniques: Clinical Proteomics